If the DCGI grants regular marketing authorisation, Covishield will be the second vaccine in the world to receive such approval. Pfizer-BioNTech's COVID-19 vaccine has received full US FDA approval for use in individuals 16 years of age and older.
Representatives from seven vaccine makers -- Serum Institute of India, Bharat Biotech, Dr Reddy's Laboratories, Zydus Cadila, Biological E, Gennova Biopharma and Panacea Biotech -- participated in the meeting.
As many as nine centres have been identified across India for this phase, including Bharati Vidyapeeth Medical College Hospital.
Biocon Biologics, a subsidiary of Biocon, on Thursday said it will offer around 15 per cent stake to Serum Institute Life Sciences at a post-money valuation of about USD 4.9 billion. Serum Institute Life Sciences (SILS) is a subsidiary of Serum Institute of India (SII).
The daily COVID-19 vaccinations crossed the 1 crore mark on Tuesday for the second time in five days, taking the total number of doses administered in the country to over 65 crore.
The trial would be held across 10 sites and would cover 920 children -- 460 each in the age groups of 12-17 and 2-11 -- according to official sources.
The government thinks that this move is feasible now because there are many vaccines available for the people, apart from Covishield and Covaxin, and also because there is a sufficient amount of vaccines available in the country.
Cyrus Poonawalla on Friday strongly affirmed that mixing two different vaccines of COVID-19 is a very risky decision and it is must be discouraged.
If cocktail vaccines are administered and if the result is not good, then SII may say that another vaccine was not good, vice versa, the other company might say that since you mixed Serum's vaccine, it did not give desired results, Poonawalla said.
The shortage is going to end soon because the United States has purchased Pfizer’s vaccine which will start to come online in August, said USAID Administrator Samantha Power.
The RDIF and Serum Institute of India, the world’s largest vaccine producer, will start production of Sputnik V vaccine in September.
A decline in average daily vaccination against the coronavirus has been seen since June 21, when the new phase of universalisation of COVID-19 vaccination commenced, government data showed.
The Pune mayor on Sunday said that the Covishield will not be available at any vaccination centre under the jurisdiction of Pune Municipal Corporation today.
According to information provided to the Drugs Controller General of India (DCGI) by the Pune-based Serum Institute of India, it has sent 45 batches of Covishield, amounting to 10. 80 crore doses, to the Central Drugs Laboratory, Kasauli for release in June so far
More than 1.45 crore COVID-19 vaccine doses are still available with states and union territories and over 19,10,650 jabs are in the pipeline.
“We are now urgently trying to work with AstraZeneca itself as well as SII, the Government of India to restart those shipments so that we can get those second doses into those populations because we are running” to a longer interval “than we would have liked,” a WHO official said.
The US-based biotechnology company Novavax has tied up with the Serum Institute of India (SII) to manufacture its Covid-19 vaccine, namely Covovax.
Novavax has tied up with the Serum Institute of India (SII) to manufacture its Covid-19 vaccine, namely Covovax.
The DCGI has granted permission to the Serum Institute of India (SII) to manufacture the Sputnik COVID-19 vaccine in India for examination, test and analysis with certain conditions.
Pune-based SII has collaborated with Gamaleya Research Institute of Epidemiology and Microbiology, Moscow in Russia for developing Sputnik V at its licensed Hadapsar facility.
Top News
Latest News
